Why compare them?
Both are represented in Type 2 diabetes research, making their overlapping mechanisms and evidence maturity useful to compare.
Simple first. Deeper when you want it.
Understand the differences that matter.
See the biggest similarities, differences, strengths, limitations, and unanswered questions first—then open the evidence behind them.
Compound comparison
Retatrutide vs. Semaglutide
Understand the meaningful overlap, differences, evidence, and unknowns—then go deeper only when you want to.
60-Second Summary
The answer first
Current evidenceComparable evidence base
No direct head-to-head study is represented. This comparison uses separate evidence records that may differ in population, duration, route, dose, and endpoint.
✓ Shared
Shared Similarities
- Both records include GLP-1R.
- Both have been studied in Type 2 diabetes.
- Both have controlled human research, although the questions and designs may differ.
⇄ Different
Biggest Difference
Retatrutide is distinguished by triple agonist: it shares GIP and GLP-1 receptor activity with tirzepatide and adds glucagon-receptor activity; Semaglutide is distinguished by single GLP-1 receptor agonist with multiple approved injection and tablet products and mature outcomes evidence.
? Unknown
Biggest Unknown
No direct head-to-head study establishes how these compounds compare under the same population, dose, duration, and endpoints.
Key Takeaways
Retatrutide is distinguished in the current record by triple agonist: it shares GIP and GLP-1 receptor activity with tirzepatide and adds glucagon-receptor activity. Semaglutide is distinguished by single GLP-1 receptor agonist with multiple approved injection and tablet products and mature outcomes evidence. Neither is objectively “better”; the useful question is which evidence record addresses the research question being asked.
Research matrix
Which question has stronger current support?
Research questionStronger current supportExplanation
Human evidenceSemaglutide
Retatrutide: Mixed maturity. Semaglutide: Mature human evidence.
Regulatory historySemaglutide
Retatrutide: Investigational. Semaglutide: FDA approved for defined product-specific indications.
Mechanistic breadthRetatrutide
More named targets describes mechanistic breadth; it does not establish greater effectiveness.
Direct comparisonUnknown
Separate studies cannot establish comparative superiority.
Deeper when you want it
Explore the evidence and nuance
Best-studied areas and pathway mapSee shared targets, unique pathways, and the research questions attached to each record.
Retatrutide
- Obesity
- Type 2 diabetes
- Metabolic outcomes
Semaglutide
- Weight management
- Type 2 diabetes
- Cardiovascular outcomes
- Chronic kidney disease
Pathway and research map
Shared foundation and unique questions
Research confidence by questionCompare regulatory, human-evidence, outcome, and administration records side by side.
Question by question
What each evidence base can actually answer
Regulatory statusEvidence, not a winner
RetatrutideInvestigational
Investigational. No FDA-approved indication, product label, consumer dose, or official storage procedure.
SemaglutideFDA-labeled indications
FDA approved in product-specific formulations for defined weight-management, type 2 diabetes, cardiovascular, kidney, and MASH indications.
Evidence depthEvidence, not a winner
RetatrutideMixed maturity
Phase 2 publications, one peer-reviewed Phase 3 diabetes report, and several sponsor-reported Phase 3 obesity toplines. Full pivotal obesity publications and long-term outcomes remain incomplete.
SemaglutideMature Phase 3 + outcomes
Multiple large Phase 3 programs and outcomes trials, including SELECT, FLOW, ESSENCE, STEP TEENS, and the higher-dose STEP UP program.
Weight outcomesEvidence, not a winner
RetatrutideTopline + Phase 2
TRIUMPH-1 sponsor topline: up to −28.3% mean change at 80 weeks under the efficacy estimand. A full peer-reviewed report was not located by the cutoff.
SemaglutidePeer-reviewed Phase 3
STEP 1 reported −14.9% mean change at 68 weeks with 2.4 mg versus −2.4% placebo. STEP UP later reported −18.7% with 7.2 mg, −15.6% with 2.4 mg, and −3.9% with placebo at 72 weeks.
Type 2 diabetesEvidence, not a winner
RetatrutidePeer-reviewed Phase 3
Peer-reviewed 40-week Phase 3 diabetes trial reported mean HbA1c and weight changes versus placebo.
SemaglutideApproved + extensive trials
Approved injection and oral products have extensive type 2 diabetes evidence. Product names, routes, strengths, and label instructions are not automatically interchangeable.
Obstructive sleep apnoeaEvidence, not a winner
RetatrutideRegistered; results incomplete
Included in the Phase 3 TRIUMPH program, but no peer-reviewed outcome publication was located by the cutoff.
SemaglutideNo approved indication
No FDA-approved semaglutide indication for obstructive sleep apnoea was identified in the current U.S. labels.
Cardiovascular outcomesEvidence, not a winner
RetatrutideOutcomes pending
Long-term cardiovascular and renal outcome trials are part of development; completed outcomes were not yet available.
SemaglutideSELECT + labeled uses
SELECT demonstrated fewer major cardiovascular events in adults with established cardiovascular disease and overweight or obesity without diabetes. Other approved product labels cover defined diabetes populations.
Administration and handlingEvidence, not a winner
RetatrutideTrial descriptions only
Published trial arms describe once-weekly subcutaneous administration. They are not approved dosing instructions.
SemaglutideMultiple product-specific labels
Current FDA labels include weekly subcutaneous injections and daily oral tablets with product-specific administration, switching, and storage instructions. Approved products require no reconstitution.
Comparison limitationsUnderstand what this comparison cannot establish before interpreting separate studies.
Comparable evidence base
- No direct head-to-head trial is represented for this pair.
- Separate studies may use different populations, endpoints, durations, doses, routes, and estimands.
- Results should not be interpreted as comparative superiority or individual guidance.
Current unknowns
Questions the evidence cannot answer yet
- Long-term cardiovascular, renal, and rare-event safety, plus full peer-reviewed reports from the pivotal obesity trials.
- Long-term comparative outcomes across newer products and doses, rare events at population scale, and evidence outside studied populations or approved products.
Community Intelligence
Emerging patterns, clearly separated from evidence
Retatrutide
1 published experience1/10 reports toward aggregate Community IntelligenceIndividual reports available · aggregate patterns unlock at 10
Semaglutide
No community experiences yetBe the first account holder to contribute.
Community Intelligence summarizes structured, self-reported experiences. It can reveal patterns and useful research questions, but it cannot prove safety, effectiveness, or cause and effect. Published evidence is always shown separately.